AstraZeneca PLC Files 6-K Report
Ticker: AZN · Form: 6-K · Filed: 2025-08-28T00:00:00.000Z
Sentiment: neutral
Topics: foreign-issuer, sec-filing, routine-report
Related Tickers: AZN
TL;DR
AZN filed a 6-K, standard foreign issuer report. Nothing new.
AI Summary
AstraZeneca PLC filed a Form 6-K on August 28, 2025, reporting its status as a foreign issuer. The company, formerly known as ZENECA GROUP PLC until April 22, 1993, is based in Cambridge, United Kingdom, and operates in the Pharmaceutical Preparations industry.
Why It Matters
This filing confirms AstraZeneca's ongoing reporting obligations as a foreign issuer with the SEC, providing transparency for investors.
Risk Assessment
Risk Level: low — This is a routine filing for a foreign issuer and does not contain new material financial or operational information.
Key Numbers
- 001-11960 — SEC File Number (Identifies the specific filing with the SEC)
Key Players & Entities
- AstraZeneca PLC (company) — Filer of the report
- ZENECA GROUP PLC (company) — Former name of AstraZeneca PLC
- 19930422 (date) — Date of name change from ZENECA GROUP PLC
- 20250828 (date) — Filing date and period of report
- 001-11960 (dollar_amount) — SEC file number
FAQ
What is the purpose of a Form 6-K filing?
A Form 6-K is a report of foreign issuer required by the SEC, used to furnish information which the registrant may be required to make public pursuant to the laws of the registrant's home country or which it may publish, file or make public pursuant to the laws of any stock exchange on which its securities are traded.
When was AstraZeneca PLC formerly known as ZENECA GROUP PLC?
AstraZeneca PLC was formerly known as ZENECA GROUP PLC as of April 22, 1993.
What is AstraZeneca PLC's primary industry classification?
AstraZeneca PLC's standard industrial classification is Pharmaceutical Preparations [2834].
Where is AstraZeneca PLC's principal executive office located?
AstraZeneca PLC's principal executive office is located at 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, United Kingdom.
Does AstraZeneca PLC file annual reports under Form 20-F or Form 40-F?
AstraZeneca PLC indicates it files annual reports under cover of Form 20-F.
From the Filing
0001654954-25-010131.txt : 20250828 0001654954-25-010131.hdr.sgml : 20250828 20250828111438 ACCESSION NUMBER: 0001654954-25-010131 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20250828 FILED AS OF DATE: 20250828 DATE AS OF CHANGE: 20250828 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ASTRAZENECA PLC CENTRAL INDEX KEY: 0000901832 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: X0 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-11960 FILM NUMBER: 251269183 BUSINESS ADDRESS: ADDRESS IS A NON US LOCATION: YES STREET 1: 1 FRANCIS CRICK AVENUE STREET 2: CAMBRIDGE BIOMEDICAL CAMPUS CITY: CAMBRIDGE PROVINCE COUNTRY: X0 ZIP: CB2 0AA BUSINESS PHONE: 011 44 20 7304 5000 MAIL ADDRESS: ADDRESS IS A NON US LOCATION: YES STREET 1: 1 FRANCIS CRICK AVENUE STREET 2: CAMBRIDGE BIOMEDICAL CAMPUS CITY: CAMBRIDGE PROVINCE COUNTRY: X0 ZIP: CB2 0AA FORMER COMPANY: FORMER CONFORMED NAME: ZENECA GROUP PLC DATE OF NAME CHANGE: 19930422 6-K 1 a0720x.htm HOLDING(S) IN COMPANY a0720x FORM 6-K   SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     Report of Foreign Issuer   Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934   For the month of August 2025   Commission File Number: 001-11960   AstraZeneca PLC   1 Francis Crick Avenue Cambridge Biomedical Campus Cambridge CB2 0AA United Kingdom     Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.   Form 20-F X Form 40-F __   Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):   Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______   Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.   Yes __ No X   If “Yes” is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82-_____________         AstraZeneca PLC   INDEX TO EXHIBITS     1. Holding(s) in Company   28 August 2025   On 27 August 2025, AstraZeneca PLC (the Company) was notified by The Capital Group Companies, Inc. (Capital Group) that the TR-1 notification it submitted to the Company on 25 August 2025, and which was subsequently announced by the Company on 26 August 2025, was provided in error.   Accordingly, shareholders should disregard the TR-1 notification announced by the Company on 26 August 2025 and instead refer to the TR-1 notification in relation to Capital Group announced by the Company on 21 August 2025, which is available under RNS No. 2435W / at: https://otp.tools.investis.com/clients/uk/astrazeneca/rns/regulatory-story.aspx?cid=1343&newsid=1979582&culture=en-GB&val=638918832221613810   AstraZeneca   AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit  astrazeneca.com  and follow the Company on social media  @AstraZeneca     Contacts For details on how to contact the Investor Relations Team, please click  here . For Media contacts, click  here .   Matthew Bowden Company Secretary AstraZeneca PLC   SIGN